| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pathology, Case Western Reserve University, Cleveland, OH 44106; and
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110
Decay-accelerating factor (DAF) is a complement regulator that dissociates autologous C3 convertases, which assemble on self cell surfaces. Its activity resides in the last three of its four complement control protein repeats (CCP2–4). Previous modeling on the nuclear magnetic resonance structure of CCP15–16 in the serum C3 convertase regulator factor H proposed a positively charged surface area on CCP2 extending into CCP3, and hydrophobic moieties between CCPs 2 and 3 as being primary convertase-interactive sites. To map the residues providing for the activity of DAF, we analyzed the functions of 31 primarily alanine substitution mutants based in part on this model. Replacing R69, R96, R100, and K127 in the positively charged CCP2–3 groove or hydrophobic F148 and L171 in CCP3 markedly impaired the function of DAF in both activation pathways. Significantly, mutations of K126 and F169 and of R206 and R212 in downstream CCP4 selectively reduced alternative pathway activity without affecting classical pathway activity. Rhesus macaque DAF has all the above human critical residues except for F169, which is an L, and its CCPs exhibited full activity against the human classical pathway C3 convertase. The recombinants whose function was preferentially impaired against the alternative pathway C3bBb compared with the classical pathway C4b2a were tested in classical pathway C5 convertase (C4b2a3b) assays. The effects on C4b2a and C4b2a3b were comparable, indicating that DAF functions similarly on the two enzymes. When CCP2–3 of DAF were oriented according to the crystal structure of CCP1–2 of membrane cofactor protein, the essential residues formed a contiguous region, suggesting a similar spatial relationship.
This article has been cited by other articles:
|
|
 |
|
  H. G. Hocking, A. P. Herbert, D. Kavanagh, D. C. Soares, V. P. Ferreira, M. K. Pangburn, D. Uhrin, and P. N. Barlow Structure of the N-terminal Region of Complement Factor H and Conformational Implications of Disease-linked Sequence Variations J. Biol. Chem., April 4, 2008; 283(14): 9475 - 9487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hafenstein, V. D. Bowman, P. R. Chipman, C. M. B. Kelly, F. Lin, M. E. Medof, and M. G. Rossmann Interaction of Decay-Accelerating Factor with Coxsackievirus B3 J. Virol., December 1, 2007; 81(23): 12927 - 12935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kuttner-Kondo, D. E. Hourcade, V. E. Anderson, N. Muqim, L. Mitchell, D. C. Soares, P. N. Barlow, and M. E. Medof Structure-based Mapping of DAF Active Site Residues That Accelerate the Decay of C3 Convertases J. Biol. Chem., June 22, 2007; 282(25): 18552 - 18562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Harris, D. M. Pettigrew, S. M. Lea, and B. P. Morgan Decay-Accelerating Factor Must Bind Both Components of the Complement Alternative Pathway C3 Convertase to Mediate Efficient Decay J. Immunol., January 1, 2007; 178(1): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Korotkova, I. Le Trong, R. Samudrala, K. Korotkov, C. P. Van Loy, A.-L. Bui, S. L. Moseley, and R. E. Stenkamp Crystal Structure and Mutational Analysis of the DaaE Adhesin of Escherichia coli J. Biol. Chem., August 4, 2006; 281(31): 22367 - 22377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krych-Goldberg, R. E. Hauhart, T. Porzukowiak, and J. P. Atkinson Synergy between Two Active Sites of Human Complement Receptor Type 1 (CD35) in Complement Regulation: Implications for the Structure of the Classical Pathway C3 Convertase and Generation of More Potent Inhibitors J. Immunol., October 1, 2005; 175(7): 4528 - 4535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Soares, D. L. Gerloff, N. R. Syme, A. F.W. Coulson, J. Parkinson, and P. N. Barlow Large-scale modelling as a route to multiple surface comparisons of the CCP module family Protein Eng. Des. Sel., August 1, 2005; 18(8): 379 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Servin Pathogenesis of Afa/Dr Diffusely Adhering Escherichia coli Clin. Microbiol. Rev., April 1, 2005; 18(2): 264 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Harris, R. J. M. Abbott, R. A. Smith, B. P. Morgan, and S. M. Lea Molecular Dissection of Interactions between Components of the Alternative Pathway of Complement and Decay Accelerating Factor (CD55) J. Biol. Chem., January 28, 2005; 280(4): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mark, W. H. Lee, O. B. Spiller, D. Proctor, D. J. Blackbourn, B. O. Villoutreix, and A. M. Blom The Kaposi's Sarcoma-associated Herpesvirus Complement Control Protein Mimics Human Molecular Mechanisms for Inhibition of the Complement System J. Biol. Chem., October 22, 2004; 279(43): 45093 - 45101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyagawa, T. Kubo, K. Matsunami, T. Kusama, K. Beppu, H. Nozaki, T. Moritan, C. Ahn, J. Y. Kim, D. Fukuta, et al. Delta-Short Consensus Repeat 4-Decay Accelerating Factor (DAF: CD55) Inhibits Complement-Mediated Cytolysis but Not NK Cell-Mediated Cytolysis J. Immunol., September 15, 2004; 173(6): 3945 - 3952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hudault, O. B. Spiller, B. P. Morgan, and A. L. Servin Human Diffusely Adhering Escherichia coli Expressing Afa/Dr Adhesins That Use Human CD55 (Decay-Accelerating Factor) as a Receptor Does Not Bind the Rodent and Pig Analogues of CD55 Infect. Immun., August 1, 2004; 72(8): 4859 - 4863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lukacik, P. Roversi, J. White, D. Esser, G. P. Smith, J. Billington, P. A. Williams, P. M. Rudd, M. R. Wormald, D. J. Harvey, et al. Complement regulation at the molecular level: The structure of decay-accelerating factor PNAS, February 3, 2004; 101(5): 1279 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Kuttner-Kondo, M. P. Dybvig, L. M. Mitchell, N. Muqim, J. P. Atkinson, M. E. Medof, and D. E. Hourcade A Corresponding Tyrosine Residue in the C2/Factor B Type A Domain Is a Hot Spot in the Decay Acceleration of the Complement C3 Convertases J. Biol. Chem., December 26, 2003; 278(52): 52386 - 52391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uhrinova, F. Lin, G. Ball, K. Bromek, D. Uhrin, M. E. Medof, and P. N. Barlow Solution structure of a functionally active fragment of decay-accelerating factor PNAS, April 15, 2003; 100(8): 4718 - 4723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Williams, Y. Chaudhry, I. G. Goodfellow, J. Billington, R. Powell, O. B. Spiller, D. J. Evans, and S. Lea Mapping CD55 Function. THE STRUCTURE OF TWO PATHOGEN-BINDING DOMAINS AT 1.7 A J. Biol. Chem., March 14, 2003; 278(12): 10691 - 10696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hasan, E. Pawelczyk, P. T. Urvil, M. S. Venkatarajan, P. Goluszko, J. Kur, R. Selvarangan, S. Nowicki, W. A. Braun, and B. J. Nowicki Structure-Function Analysis of Decay-Accelerating Factor: Identification of Residues Important for Binding of the Escherichia coli Dr Adhesin and Complement Regulation Infect. Immun., August 1, 2002; 70(8): 4485 - 4493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hourcade, L. Mitchell, L. A. Kuttner-Kondo, J. P. Atkinson, and M. E. Medof Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) via Sites on the Type A Domain of Bb J. Biol. Chem., January 4, 2002; 277(2): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
